Study finds GLP-1 drugs may reduce Alzheimer's risk by 12% but raise safety concerns
A new study suggests that GLP-1 drugs, such as Ozempic and Mounjaro, may lower the risk of Alzheimer's disease by 12%. The research involved 215,000 U.S. military veterans with diabetes, comparing those on GLP-1 medications to those on older treatments. The study also identified increased risks for kidney problems, pancreatitis, and gastrointestinal issues among users of GLP-1 drugs. These findings come as the Biden administration continues Medicare price negotiations for Ozempic and Wegovy. Bristol-Myers Squibb is exploring its schizophrenia drug, Cobenfy, as a potential treatment for Alzheimer's.